A detailed history of Verition Fund Management LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Verition Fund Management LLC holds 17,883 shares of DVAX stock, worth $226,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,883
Previous 14,884 20.15%
Holding current value
$226,398
Previous $167,000 19.16%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $30,139 - $34,818
2,999 Added 20.15%
17,883 $199,000
Q2 2024

Aug 14, 2024

BUY
$10.73 - $12.58 $159,705 - $187,240
14,884 New
14,884 $167,000
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $197,000 - $263,400
20,000 New
20,000 $258,000
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $1.86 Million - $3.19 Million
-249,017 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$9.75 - $14.44 $2.43 Million - $3.6 Million
249,017 New
249,017 $2.7 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.6B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.